Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANUP BANERJEE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1740213263
CMS profile
925282
Location
GASTONIA, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,025.57

115 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,636.03 113
Travel and Lodging $389.54 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANUP BANERJEE

NPI 1740213263 · CMS profile ID 925282

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

GASTONIA, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740213263?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANUP BANERJEE, NPI 1740213263, CMS profile ID 925282. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740213263?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANUP BANERJEE, NPI 1740213263, CMS profile ID 925282. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740213263?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANUP BANERJEE, NPI 1740213263, CMS profile ID 925282, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1740213263?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

115 matching records · $3,025.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 115 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–115 of 115.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $194.7701/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011862377 CMS
AstraZeneca Pharmaceuticals LP $28.7401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011911761 CMS
AstraZeneca Pharmaceuticals LP $30.4701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012003999 CMS
AstraZeneca Pharmaceuticals LP $83.7401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014965197 CMS
AstraZeneca Pharmaceuticals LP $76.9901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015430025 CMS
AstraZeneca Pharmaceuticals LP $118.2601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015791749 CMS
AstraZeneca Pharmaceuticals LP $119.2601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015882127 CMS
AstraZeneca Pharmaceuticals LP $56.7301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015969301 CMS
AstraZeneca Pharmaceuticals LP $194.7701/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016281939 CMS
Bayer Healthcare Pharmaceuticals Inc. $12.7001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000668447 CMS
Mallinckrodt Hospital Products Inc. $19.7501/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042808923 CMS
GlaxoSmithKline, LLC. $5.3501/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003248511 CMS
Amgen Inc. $14.6301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020537637 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.8301/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996462755 CMS
Novo Nordisk Inc $15.5501/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001635051 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,206.46 149
PY2020 $1,161.39 75
PY2021 $1,803.83 113
PY2022 $3,322.30 108
PY2023 $3,025.57 115
PY2024 $2,533.88 111
PY2025 $4,019.49 61

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $204,183.08 37
PY2024 Principal investigator $342,106.40 121
PY2023 Principal investigator $286,992.00 66
PY2022 Principal investigator $477,867.45 67
PY2021 Principal investigator $402,864.55 93
PY2020 Recipient $2,874.84 33
PY2020 Principal investigator $142,701.65 68
PY2019 Recipient $159.00 1
PY2019 Principal investigator $180,118.00 149

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $52,400.79 12/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554191
Principal investigator 1 Genentech, Inc. $2,266.00 12/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211587489
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.06 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738209
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.48 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738211
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738213
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738215
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.40 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738217
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738219
Principal investigator 1 Genentech, Inc. $4,360.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587481
Principal investigator 1 Genentech, Inc. $10,307.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587486
Principal investigator 1 Verona Pharma, Inc. $6,808.81 10/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891943
Principal investigator 1 GlaxoSmithKline, LLC. $845.00 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192163216
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738187
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738189
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738191
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738193
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738195
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738197
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $253.50 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738199
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,000.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738201
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $360.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738205
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,550.00 09/12/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738207
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,489.44 08/21/2025 Non-covered Recipient Entity
Clinical Research of Gastonia
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738203
Principal investigator 1 Verona Pharma, Inc. $9,200.00 08/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891853
Principal investigator 1 Verona Pharma, Inc. $1,481.00 08/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891855
Principal investigator 1 Genentech, Inc. $12,051.00 07/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587477
Principal investigator 1 Genentech, Inc. $16,933.00 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587473
Principal investigator 1 GlaxoSmithKline, LLC. $1,130.22 04/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192163197
Principal investigator 1 GlaxoSmithKline, LLC. $1,535.75 04/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192163193
Principal investigator 1 GlaxoSmithKline, LLC. $1,425.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192163202
Principal investigator 1 GlaxoSmithKline, LLC. $116.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192163211
Principal investigator 1 GlaxoSmithKline, LLC. $1,359.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192165694
Principal investigator 1 GlaxoSmithKline, LLC. $402.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192165698
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192163206
Principal investigator 1 GlaxoSmithKline, LLC. $5,045.00 02/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192163221
Principal investigator 1 Genentech, Inc. $35,855.00 02/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,740.23 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF GASTONIA
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185549471